What we do Supriya Lifescience Ltd is a leading Indian manufacturer and exporter of over 39 active pharmaceutical ingredients (APIs) across diverse therapeutic segments such as antihistamines and anesthetics. |
Founded in 1,985 |
Market share Dominant exporter in Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate with 45-70% market share in India. |
Problem solved Provides essential APIs globally focusing on quality, regulatory compliance, and backward integration to ensure price competitiveness and supply security. |
Top clients or who we serve Supplies to over 1,500 customers in 120+ countries, primarily B2B serving pharmaceutical companies in regulated and emerging markets. |
Key management - |
Our journey and innovations Started as a partnership in 1985; converted to public limited company in 2008; multiple international regulatory approvals; ongoing capacity expansions. |
Where we operate Exports to over 120 countries, including regulated markets like the US, Europe, China, and emerging markets globally. |
Top products or what we offer Manufactures 39+ APIs focusing on antihistamines, analgesics, anesthetics, vitamins, anti-asthmatics, and anti-allergics. |
Top brands Chlorpheniramine Maleate, Ketamine Hydrochloride, Salbutamol Sulphate - market leaders and key revenue drivers. |
Raw materials needed Specialty chemicals and intermediates for complex API synthesis across multiple chemistries. |
Raw materials supplier Primarily in-house through backward integration, supplemented by external vendors to ensure supply chain stability. |
Recurring vs cyclical contribution Revenue is largely recurring via long-term contracts and ongoing API supply to pharmaceutical firms. |
Our industry position Among largest Indian API exporters with strong regulatory compliance and integrated manufacturing facilities. |
Financial highlights FY2025 revenue: Rs 6,965 million; Net profit: Rs 1,880 million; strong growth and stable profitability. |
Geographical revenue split Diversified revenue from Asia, Europe, North America, Latin America, and other regions with no dominant geography. |
Order book - |
Whats driving growth R&D-led new product development, capacity expansion, backward integration, and growing global pharmaceutical demand. |
Our future plans Expand backward integration, commission new formulation facility, increase manufacturing capacity, and grow CDMO/CMO partnerships. |
Our green promise Environmental compliance with advanced effluent treatment, safety initiatives, and resource conservation programs. |
Our people and values Employee-centric culture with emphasis on safety, training, diversity, and ethical business practices. |
Key challenges ahead Regulatory compliance risks, raw material availability, market competition, and geopolitical uncertainties. |
Interesting facts Largest Indian exporter of key APIs contributing over 50% of India’s export volume in major products. |
Risks and strategy Mitigates risks via backward integration, diversified markets, strong quality systems, and disciplined financial controls. |
